UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000008627
Receipt number R000010026
Scientific Title Study of high-dose Pitavastatin on lipid and glucose metabolism disorder in Coronary Artery Disease. (Shield-CAD)
Date of disclosure of the study information 2012/08/08
Last modified on 2012/08/06 08:30:35

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Study of high-dose Pitavastatin on lipid and glucose metabolism disorder in Coronary Artery Disease.
(Shield-CAD)

Acronym

Study of high-dose Pitavastatin on lipid and glucose metabolism disorder in Coronary Artery Disease.
(Shield-CAD)

Scientific Title

Study of high-dose Pitavastatin on lipid and glucose metabolism disorder in Coronary Artery Disease.
(Shield-CAD)

Scientific Title:Acronym

Study of high-dose Pitavastatin on lipid and glucose metabolism disorder in Coronary Artery Disease.
(Shield-CAD)

Region

Japan


Condition

Condition

Patients with stable coronary artery disease

Classification by specialty

Cardiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Examine the HbA1c levels in patients of coronary artery disease with hypercholesterolemia, treated with some strong statin, when one statin switches to high-dose of pitavastatin.

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Change and percent change in HbA1c at 3, 6 months after administration

Key secondary outcomes

Change and percent change in TC, LDL-C, HDL-C, TG, Scr, microalbuminuria, eGFR, FBS, IRI, HOMA-IR, ApoA1, ApoB, ApoE and SAA at 3, 6, 9, 15 months after administration.


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Administration of atorvastatin 10mg or rosuvastatin 2.5mg or pitavastatin 2mg in the first 3 months, followed by the administration of pitavastatin 4mg for 12 months.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

(1) Coronary artery disease patients
Meeting one of following events
1) History of Acute Coronary Syndrome (AMI or Unstable angina)
2) History of revascularization (PCI or CABG)
3) Diagnosis of ischemic heart disease and coronary artery stenosis as having 75% or higher stenosis according to the AHA classification
(2) Hypercholesterolemia patients
Meeting one of following criteria
1) LDL-C is 100 mg/dL or over and requiring cholesterol lowering drugs judged by attending physicians
2) Patents receiving cholesterol lowering drugs
(3) Age (20year old<=)
(4) Patients given written informed consent.

Key exclusion criteria

Exclusion Criteria
1. Patients planed revascularization
2. Patients with occurrence of acute coronary syndrome (AMI or Unstable angina) within 3 months
3. Patients who have been undergone PCI or CABG within 3 months
4. Malignant tumor in active phase
5. Patients who have hypersensitivity to LIVALO, Lipitor, CRESTOR tablet
6) Patients who have severe liver dysfunction or biliary atresia.
7)Patients who are being treated with cyclosporine
8) Pregnant women, women suspected of being pregnant, or lactating women
9. Patients with prohibited drugs
10. Patients who received insulin therapy.
11. Patients who changed diabetes therapy within 3 months before entry.
12. Patients who received cholesterol-lowering agents except statin within a month before entry.
13. Patients undergoing dialysis
14. Patients with familial hypercholesterolemia
15. Patients who are ineligible in the opinion of the investigator

Target sample size

100


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Miyakoshi Kazuho

Organization

Minami-Osaka Hospital

Division name

Department of Cardiovascular Medicine

Zip code


Address

1-18-18 Higashikagaya, Suminoe-ku, Osaka ,Japan

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name Miyakoshi Kazuho

Organization

Minami-Osaka Hospital

Division name

Department of Cardiovascular Medicine

Zip code


Address

1-18-18 Higashikagaya, Suminoe-ku, Osaka ,Japan

TEL


Homepage URL


Email



Sponsor or person

Institute

Minami-Osaka Hospital

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2012 Year 08 Month 08 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2012 Year 05 Month 08 Day

Date of IRB


Anticipated trial start date

2012 Year 06 Month 01 Day

Last follow-up date

2014 Year 09 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2012 Year 08 Month 06 Day

Last modified on

2012 Year 08 Month 06 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000010026


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name